

CONTENTS

<i>Preface</i>	v
Chapter 1 Using Biosensors to Probe Fundamental Questions of Sleep	1
<i>Erik Naylor and Peter A. Petillo</i>	
1.1 Introduction	1
1.2 Sleep — A Beneficial Unknown	1
1.3 Electroencephalographic Sleep Measurement	2
1.4 Early Investigations of Sleep Physiology	4
1.5 Biosensor Recording during Sleep	5
1.5.1 Biosensor Basics	5
1.5.2 Biosensor Studies during Sleep	6
1.5.2.1 Glucose	7
1.5.2.2 Lactate	9
1.5.2.3 Glutamate	11
1.5.2.4 Adenosine	13
1.6 Biosensors and the Astrocyte Neuron Lactate Shuttle Hypothesis	15
1.7 Conclusion	18
Acknowledgments	20
References	20
Chapter 2 Cortical Cholinergic Transients for Cue Detection and Attentional Mode Shifts	27
<i>Martin Sarter, William M. Howe and Howard Gritton</i>	
2.1 Introduction	27
2.2 Measurement of Second-Based Cholinergic Transients	31
2.3 Cue Detection Mediated by Cholinergic Transients	32

2.4 Cholinergic Mediation of Cue Detection in Trials Involving an Attentional Mode Shift	33
2.5 Gamma Synchrony as a Neurophysiological Marker of Cholinergic Modulation of Cortical Circuitry	35
2.6 Moving Forward: Potential Neurobiological Impact of New Electrodes and Recording Methods	37
2.7 Summary and Conclusions	38
Acknowledgment	40
References	40
 Chapter 3 Real-Time Measurement of ATP and Adenosine in the Nervous System	45
<i>Nicholas Dale</i>	
3.1 Introduction	45
3.1.1 The Components of Purinergic Signaling	45
3.1.1.1 ATP receptors and release mechanisms	46
3.1.1.2 Adenosine receptors and release mechanisms	47
3.1.1.3 Ectonucleotidases — breakdown of ATP and initiation of ADP and adenosine signaling	48
3.1.1.4 The need for real-time measurements of ATP and adenosine	49
3.2 ATP-Release, Signaling and Functions	50
3.2.1 ATP Biosensing Principles	50
3.2.2 The Role of ATP Signaling in Chemosensing	51
3.2.2.1 Central CO ₂ chemoreception	51
3.2.2.2 Glucosensing in the hypothalamus	54
3.2.3 ATP Signaling and Development	57
3.2.3.1 Initiation of expression of the eye-field transcription factors	57
3.2.3.2 Regulation of development of the retina	59
3.3 Adenosine-Release Mechanisms and Functions	59
3.3.1 Adenosine Biosensing Principles	59
3.3.2 Activity Dependence of Adenosine Release	60
3.3.2.1 Release mechanisms in cerebellum	61
3.3.2.2 Release mechanisms in hippocampus	63
3.3.2.3 Adenosine release linked to activation of the Na ⁺ -K ⁺ ATPase	63
3.3.2.4 What have we learned?	64
3.3.3 Sleep and Adenosine	65

3.4 Interplay between ATP and Adenosine Release:	
Motor Pattern Generation	67
3.5 Concluding Remarks	70
Acknowledgments	70
References	70
 Chapter 4 Electrochemical Detection of Adenosine <i>In Vivo</i>	79
Ashley E. Ross and B. Jill Venton	
4.1 Introduction	79
4.1.1 Adenosine Regulation in the Central Nervous System	79
4.1.1.1 Intra- and extracellular formation of adenosine	80
4.1.1.2 Adenosine receptors	80
4.1.1.3 Adenosine transporters	81
4.1.2 Function of Adenosine in the Central Nervous System	82
4.1.2.1 Adenosine as a neuroprotector	82
4.1.2.2 Adenosine as a neuromodulator	83
4.2 Electrochemical Detection of Adenosine <i>In Vivo</i>	84
4.2.1 Adenosine Characterization using FSCV	84
4.2.1.1 Characterization of carbon-fiber microelectrodes for adenosine detection using FSCV	87
4.2.1.2 Characterization of diamond electrodes for adenosine detection using FSCV	87
4.2.1.3 Adenosine modulates respiratory rhythmogenesis	88
4.2.1.4 Short electrical stimulations elicit rapid adenosine changes	88
4.2.1.5 Adenosine transiently regulates oxygen concentrations	88
4.2.1.6 A ₁ receptors self-regulate stimulated adenosine release	89
4.2.1.7 Stimulated adenosine release is activity-dependent in multiple brain regions	89
4.2.1.8 FSCV to study adenosine deaminase kinetics	91
4.2.1.9 Adenosine release during deep brain stimulation (DBS) causes microthalamotomy effect	92
4.2.1.10 AMP hydrolysis to adenosine inhibits pain-sensing response in spinal cord	92
4.2.1.11 Enhanced understanding of adenosine signaling using FSCV	95

4.2.2 Adenosine Characterization using Amperometric Adenosine Micro-Biosensors	95
4.2.2.1 Activity-dependent adenosine release in the cerebellum is modulated by endogenous neurotransmitters	96
4.2.2.2 Adenosine is released during hypoxia in the hippocampus	98
4.2.2.3 Adenosine is released during hypoxia in the nucleus tractus solitarii (NTS) of the brainstem	99
4.2.2.4 Adenosine is released during ischemia	99
4.2.2.5 Adenosine modulates chemoreceptor responses	100
4.2.2.6 Adenosine is linked to modulating seizures induced by CO ₂	100
4.2.2.7 Increase in extracellular adenosine levels provides anticonvulsant behavior during epilepsy	100
4.2.2.8 Adenosine is involved in the sleep-wake cycle	101
4.2.2.9 Enhanced understanding of adenosine signaling using amperometric biosensors	102
4.3 Contributions of Electrochemical Detection of Adenosine to the Field	102
Acknowledgments	105
References	105
Chapter 5 Real-Time <i>In Vivo</i> Neurotransmitter Measurements Using Enzyme-Based Ceramic Microelectrode Arrays: What We Have Learned About Glutamate Signaling	113
Jason J. Burmeister, Erin R. Hascup, Kevin N. Hascup, Verda Davis, Seth R. Batten, Francois Pomerleau, Jorge E. Quintero, Peter Huettl, Pooja M. Talauliker, Ingrid Strömberg, Greg A. Gerhardt	
5.1 Introduction	113
5.2 Materials and Methods	115
5.2.1 Development of Ceramic-Based MEAs	115
5.2.2 Basic Capabilities of MEAs	115
5.3 Self-Referencing Recordings using Amperometry: How to Measure Resting Levels of Neurochemicals	116
5.3.1 Why Perform Self-Referencing Recordings?	116

5.4 Applications to Biological Systems	119
5.4.1 Studies in Freely Moving Rats and Mice	119
5.4.2 Tonic Release of Neurotransmitters: Is It Neuronally-Derived?	120
5.4.2.1 How do we know that we are measuring glutamate that is mostly derived from neurons?	120
5.4.2.2 Resting levels of glutamate in the CNS: comparisons to microdialysis measurements	121
5.4.3 Beyond Tonic Recordings: Phasic Release of Neurotransmitters	123
5.4.4. Chronic Implantation: Histopathology and Biocompatibility	124
5.5 Conclusions	128
Acknowledgments	129
References	129
 Chapter 6 Enzyme-Based Microbiosensors for Selective Quantification of Rapid Molecular Fluctuations in Brain Tissue <i>Leyda Z. Lugo-Morales and Leslie A. Sombers</i>	 137
6.1 Introduction	137
6.1.1 Electrochemistry in Neuroscience	137
6.1.2 Electrochemical Detection of Non-Electroactive Analytes	138
6.1.3 Electrochemical Biosensors	138
6.2 Amperometric Biosensors	139
6.2.1 Platinum (Pt)-Based Biosensors	139
6.2.2 Methods of Enzyme Immobilization	140
6.2.2.1 Encapsulation or entrapment	140
6.2.2.2 Adsorption	141
6.2.2.3 Covalent attachment and cross-linking	141
6.2.3 Self-Referencing Amperometric Biosensors	141
6.2.4 Applications	142
6.2.4.1 Acetylcholine	142
6.2.4.2 Glutamate	144
6.2.4.3 Glucose	146
6.3 Voltammetric Biosensors	147
6.3.1 Carbon-Fiber Microelectrodes	147
6.3.2 Enzyme Encapsulation within Chitosan by Electrodeposition	148
6.3.3 Enzyme-Modified Carbon-Fiber Microelectrodes for the Detection of Non-Electroactive Analytes using FSCV	148

6.3.4 High-Resolution Sampling of Brain Glucose Concentration Fluctuations	152
6.4 Conclusions	153
Acknowledgments	154
References	154
 Chapter 7 Monitoring and Modulating Dopamine Release and Unit Activity in Real-Time	161
<i>Anna M. Belle and R. Mark Wightman</i>	
7.1 Introduction	161
7.2 Dopamine Neurotransmission	162
7.3 Evolution of A Waveform	164
7.4 Seeing the Brain Communicate: A Combination of Measurement Procedures	166
7.4.1 Combining Electrochemistry with Electrophysiology	167
7.4.2 Controlled Iontophoresis	171
7.5 Conclusions	173
Acknowledgments	173
References	173
 Chapter 8 Quantitative Chemical Measurements of Vesicular Transmitters with Single Cell Amperometry and Electrochemical Cytometry	181
<i>Jelena Lovrić, Xianchan Li, Andrew G. Ewing</i>	
8.1 Introduction	181
8.2 Electrochemical Cytometry	183
8.3 Mathematical Treatment of Amperometric Data: Partial Distention During Exocytosis Explains The Shape of Amperometric Events	186
8.3.1 Simplified Discussion of the Mathematical Approach	186
8.3.2 Modeling Supports the Hypothesis that Vesicle Pore Opening Does Not Need to be Full	189
8.3.3 Implication that Lipids Control the Pore Once it is Open	190
8.4 Regulation of Open-and-Closed Exocytosis	190
8.4.1 Evidence that Dynamin Regulates the Opening of the Fusion Pore	190
8.4.2 Evidence that Actin Regulates the Closing of the Fusion Pore	192
8.5 Post-Spike Foot is Observed in Amperometry	193

8.5.1 Observation of Post-Spike Feet	193
8.5.2 Variation of Lipids Confirms Validity of Post-Spike Feet	197
8.5.3 Some Exocytosis Events Appear to Open All The Way	197
8.6 Future Perspectives	198
Acknowledgments	198
References	198
Chapter 9 Coupling Voltammetry With Optogenetics to Reveal Axonal Control of Dopamine Transmission by Striatal Acetylcholine	201
<i>Polina Kosillo, Katherine R. Brimblecombe, Sarah Threlfell and Stephanie J. Cragg</i>	
9.1 Introduction	201
9.1.1 DA Detection with FCV	202
9.1.2 Driving Neural Activity in Local Striatal Circuits: Electrical Stimulation <i>Versus</i> Optogenetics	203
9.1.3 Elucidating the Role of ChIs in Striatal DA Transmission	203
9.2 Optogenetic Activation of Striatal Cholinergic Interneurons Drives Dopamine Transmission	204
9.2.1 Methodology for Combined FCV and Optogenetics	205
9.2.2 Key Findings	206
9.3 Critical Methodological Issues	207
9.3.1 ChR2 Expression Method: Local Targeting <i>Versus</i> Transgenic Breeding Approaches	208
9.3.2 Choice of AAV	210
9.3.2.1 ChR2 expression levels	211
9.3.2.2 Axonal expression of ChR2 and post-injection delays	211
9.3.3 Choice of fluorescent tag	212
9.3.4 Laser or LED	212
9.3.5 Laser Power and Pulse Duration	214
9.3.6 Electrochemical Analysis	214
9.3.6.1 Photoelectric effect of CFM photo-activation	214
9.3.6.2 Drugs as photo- and electroactive compounds	215
9.3.7 Physiological Relevance	215
9.3.7.1 Physiological firing frequencies	216
9.3.7.2 Synchrony and selective activation of projection pathways	216

9.4 Summary	217
Acknowledgment	217
References	217
Chapter 10 Electrochemical Recordings During Deep Brain Stimulation in Animals and Humans: WINCS, MINCS, and Closed-Loop DBS	225
<i>Charles D. Blaha, Su-Youne Chang, Kevin E. Bennet and Kendall H. Lee</i>	
10.1 Introduction	225
10.1.1 DBS is a State-of-the-Art Neurosurgical Therapy	226
10.1.2 DBS Mediated DA Release in the Basal Ganglia: Pre-Clinical Studies	229
10.2 Preliminary Neurochemical Studies	229
10.2.1 STN DBS Affects Striatal DA Release in the Anesthetized Rat	231
10.2.2 Effects of Various STN DBS Parameters on Striatal DA Release in the Anesthetized Rat	232
10.3 Neurotransmitter Monitoring Systems	235
10.3.1 WINCS	235
10.3.2 MINCS	236
10.4 Recording Electrode Development	238
10.4.1 Microelectrode for Human Neurochemical Recording	238
10.5 Neurochemical Recordings in Large Animals and Neurological Patients	239
10.5.1 DA and ADO Recording in the Pig	239
10.5.2 Human Neurochemical Recordings	243
10.6 Conclusion and Future Directions	244
Acknowledgment	244
References	244
Chapter 11 Sweet Leaf: Neurochemical Advances Reveal How Cannabinoids Affect Brain Dopamine Concentrations	251
<i>Erik B. Oleson and Joseph F. Cheer</i>	
11.1 Introduction	251
11.2 Real-Time Monitoring of Cannabinoid Actions on Dopamine	252
11.2.1 Cannabinoids, Microdialysis, and Tonic Dopamine Concentrations	252
11.2.2 Novel Insights from FSCV	253

11.2.3 A Current Theory on the Pharmacological Mechanism of Cannabinoid Action	254
11.3 The Endocannabinoid System	255
11.3.1 Introduction	255
11.3.2 Endocannabinoids, Microdialysis and Tonic Dopamine Concentrations	256
11.3.3 Novel Insights from FSCV	257
11.4 Future Prospects	261
Acknowledgment	263
References	263
 Chapter 12 Probing Serotonin Neurotransmission: Implications for Neuropsychiatric Disorders	269
<i>Kevin M. Wood, David Cepeda and Parastoo Hashemi</i>	
12.1 Introduction	269
12.2 Real-Time Serotonin Monitoring	270
12.2.1 Microdialysis	270
12.2.2 Constant Potential Amperometry	271
12.2.3 High Speed Chronoamperometry	272
12.2.4 Fast-Scan Cyclic Voltammetry (FSCV)	272
12.3 The Relevance of Real-Time Serotonin Measurements to Physiology and Disease	273
12.3.1 Endogenous <i>In Vivo</i> Processes	274
12.3.2 Serotonin Modulation	275
12.3.3 Serotonin Clearance	276
12.3.4 Serotonin's Involvement in Disease	278
12.4 Conclusions	279
References	279
 Chapter 13 Voltammetric Analysis of Loss and Gain of Dopamine Function	287
<i>Paul A. Garriss, Kristen A. Keefe</i>	
13.1 Introduction	287
13.2 Modes of Dopamine Signaling: Overview	288
13.3 Dopamine Signaling in the Dopamine-Depleted Brain	289
13.3.1 Passive Stabilization of Tonic Dopamine Signaling	289
13.3.2 Compensatory Up-Regulation of Exocytotic Dopamine Release	292
13.3.3 Deficits in Phasic Dopamine Signaling	293
13.3.4 Deficits in Postsynaptic Gene Expression	295
13.4 Mechanism of AMPH Action	297

13.4.1 Activation, not Disruption, of Phasic Dopamine Signaling	297
13.4.2 AMPH-Induced Up-Regulation of Exocytotic Dopamine Release	300
13.4.3 Reconciling Phasic Activation and Dopamine Efflux	302
13.5 Summary and Conclusion	304
Acknowledgment	304
References	304
 Chapter 14 Measurements of Dopamine Release and Uptake in Huntington's Disease Model Rodents <i>Sam V. Kaplan, Stephen C. Fowler, and Michael A. Johnson</i>	 311
14.1 Introduction	311
14.2 Potential Mechanisms of Neuronal <i>Dysfunction and Degradation in HD</i>	314
14.3 Genetically Engineered HD Model Rodents	314
14.4 Microdialysis Studies in HD Model Rodents	316
14.5 Voltammetric Measurements of DA Release and Uptake in HD Model Rodents	317
14.5.1 FSCV	317
14.5.2 DA Release and Uptake Measurements in R6/2 and R6/1 HD Model Mice	318
14.5.3 Mechanisms of Neurotransmitter Release Impairment	319
14.5.4 DA Release and Uptake Measurements in HD Model Rats	322
14.5.4.1 Treatment with 3-NP	322
14.5.4.2 HDtg Rats	324
14.6 Conclusion	328
Acknowledgments	329
References	329
 Chapter 15 Characterizing Neuropeptide Release: From Isolated Cells to Intact Animals <i>Agatha E. Maki and Jonathan V. Sweedler</i>	 335
15.1 Introduction	335
15.2 History of Characterizing Neuropeptide Release	337
15.3 Current Methods of Analyzing Neuropeptide Release	338

15.3.1 Cellular Methods	338
15.3.2 Intact Tissue Methods	341
15.3.3 <i>In vivo</i> Methods	342
15.4 Conclusions	344
Acknowledgment	344
References	345
 Chapter 16 Advancing Chronic Intracortical Electrode Recording Function	 351
<i>Lobitash Karumbaiah, Tarun Saxena, and Ravi Bellamkonda</i>	
16.1 Introduction	351
16.2 Cortical Electrodes for Real-Time Monitoring of Neural Activity	352
16.2.1 Non-Invasive Scalp Electrodes for Measurement of EEG Activity	352
16.2.2 Minimally Invasive Subdural Electrodes for Measurement of EcoG Activity	353
16.2.3 Invasive Intracortical Electrodes for Measurement of Single Unit Activity	354
16.3 FBR to Intracortical Electrodes	356
16.3.1 Brain Response to Intracortical Electrode Implants	356
16.3.1.1 Acute response	357
16.3.1.2 Chronic response	357
16.3.2 Current Methods of Assessment	358
16.3.2.1 Histology	358
16.3.2.2 Impedance spectroscopy	358
16.3.2.3 Cyclic voltammetry	359
16.3.3 Advanced Molecular Methods	360
16.3.3.1 Non-invasive imaging of the BBB	360
16.3.3.2 Inflammatory cytokine signaling	362
16.4 Conclusions	363
References	363
 Chapter 17 Measurement of Cytokines in the Brain	 369
<i>Julie A. Stenken and Michael Elkins</i>	
17.1 Introduction	369
17.2 Cytokines as Signaling Proteins	370

17.3 Clinical Interests in Cytokines in the Brain	371
17.4 Overview of Common Methods for Cytokine Measurements and Tissue Mapping	372
17.5 Cellular Sources of Cytokines	373
17.5.1 CCL2 (MCP-1)	374
17.5.2 CXCL12 (SDF-1)	374
17.5.3 CX3CL1	376
17.5.4 IL-1 β	376
17.5.5 IL-6	377
17.6 Cytokine Collection from Brain ECS	377
17.6.1 Sampling Considerations: Overview of Mass Transport, Binding, and Uptake Processes	378
17.6.2 Push-Pull Perfusion	380
17.6.2.1 Device calibration	380
17.6.3 Microdialysis Sampling	381
17.6.3.1 Microdialysis sampling device calibration	382
17.6.4 Selected Applications of Cytokine Collection	383
17.6.4.1 Push-Pull perfusion applications for cytokine collection	383
17.6.4.2 Microdialysis applications for cytokine collection	384
17.7 Cytokine Production During Brain Injuries and Other Device Implantation Procedures	388
17.8 Conclusions and Future Prospects	390
Acknowledgments	391
References	391
<i>Index</i>	401